查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1657251

癌症诊断液态切片市场：2034 年的机会与策略

Liquid Biopsy For Cancer Diagnostics Global Market Opportunities And Strategies To 2034
出版日期: | 出版商: The Business Research Company | 英文 262 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2019 年全球癌症诊断液态切片市场价值为 44.4647 亿美元，到 2024 年的复合年增长率将超过 15.00%。

政府在医疗保健领域的研发倡议

在预测期内，政府在医疗保健领域的研发倡议支持了癌症诊断液态切片活检市场的成长。政府措施是指各级政府当局（地方、区域、国家和国际）为解决具体问题、实现具体目标和为社会带来积极计划而采取的具体行动、计划、政策和项目。政府的研发倡议将透过鼓励创新、合作、法律规范、公众意识提升、医疗服务取得、资料共用等方式，为推动癌症诊断液态切片提供关键支持。例如，2023年11月，英国和法国宣布建立合作伙伴关係，以应对癌症研究中的关键挑战。这次法国国家癌症研究所 (INCa) 与英国癌症研究中心 (英国领先的慈善机构，资助各类癌症研究) 之间的合作致力于资助顶尖专家解决最复杂的癌症病例。两个组织将共同捐赠 860 万英镑（1,080 万美元）来支持全球癌症大挑战倡议并推动世界一流的癌症研究工作。因此，政府在医疗保健领域的研发倡议支持了癌症诊断液态切片活检市场的成长。

目录

第一章执行摘要

  • 癌症诊断液态切片—市场吸引力和宏观经济条件

第 2 章 目录

第 3 章表格一览

第四章图表一览

第五章 报告结构

第六章 市场特征

  • 一般市场定义
  • 概述
  • 癌症诊断液态切片市场定义和细分
  • 市场区隔：按类型
    • 产品
    • 服务
  • 市场区隔：按癌症
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 其他癌症
  • 市场区隔：依样品
    • 血
    • 尿
    • 唾液
  • 市场区隔：按最终用户
    • 医院
    • 诊断中心
    • 其他最终用户

第七章：主要市场趋势

  • 用于识别癌症生物标誌物的高精度液态切片
  • 肿瘤学和产前护理领域自动液态切片技术的进展
  • 下一代液态切片工具可提高癌症检测能力
  • 个人化癌症治疗液态切片技术进展
  • 利用液态切片增强肿瘤检测和分析

8. 癌症诊断液态切片市场-宏观经济情景

  • COVID-19 的影响：癌症诊断液态切片市场
  • 乌克兰战争的影响：癌症诊断液态切片市场
  • 高通膨的影响：癌症诊断液态切片市场

第九章 全球市场规模及成长

  • 市场规模
  • 2019 年至 2024 年市场成长表现
    • 市场驱动因素 2019-2024
    • 2019 至 2024 年市场限制
  • 2024-2029 年及 2034 年市场成长预测
    • 市场驱动因素 2024-2029
    • 市场限制 2024-2029

第 10 章全球癌症诊断液态切片市场细分

  • 全球癌症诊断液态切片市场：按类型、表现和预测，2019-2024 年、2029 年、2034 年
  • 全球癌症诊断液态切片市场：按癌症类型、表现和预测，2019-2024 年、2029 年、2034 年
  • 全球癌症诊断液态切片市场：按最终用户、绩效和预测，2019-2024 年、2029 年预测、2034 年预测
  • 全球癌症诊断液态切片市场：按样本、表现和预测，2019-2024 年、2029 年预测、2034 年预测

第 11 章癌症诊断液态切片市场：区域和国家分析

  • 全球癌症诊断液态切片市场：按地区、绩效及预测，2019-2024 年、2029 年、2034 年
  • 全球癌症诊断液态切片市场：按国家/地区划分、绩效及预测，2019-2024 年、2029 年、2034 年

第十二章 亚太市场

第十三章 西欧市场

第十四章 东欧市场

第十五章 北美市场

第十六章 南美洲市场

第十七章 中东市场

第 18 章：非洲市场

第十九章竞争格局与公司概况

  • 公司简介
  • F. Hoffman-La Roche Ltd
  • Thermo Fisher Scientific Inc
  • Guardant Health Inc
  • Illumina Inc.
  • Exact Sciences Corporation

第 20 章 其他大型创新企业

  • Natera Inc.
  • Johnson & Johnson Services Inc.
  • Bio-Rad Laboratories Inc.
  • Caris Life Science
  • Sysmex Corporation
  • Qiagen NV
  • Myriad Genetic Laboratories Inc.
  • Invitae Corporation
  • Freenome Holdings Inc.
  • Tempus Labs, Inc.
  • MDxHealth SA
  • NeoGenomics Laboratories Inc.
  • ExosomeDx
  • Biodesix Inc.
  • Biocartis Group NV.

第 21 章 竞争性基准化分析

第 22 章 竞争仪錶板

第23章 重大併购

  • Quest Diagnostics Acquired Haystack Oncology
  • Exact Sciences Corporation Acquired Resolution Bioscience, Inc.
  • Exact Sciences Corporation Acquired Thrive Earlier Detection

第24章机会与策略

  • 2029 年全球癌症诊断液态切片市场：提供新机会的国家
  • 2029 年全球癌症诊断液态切片市场：细分市场将带来新机会
  • 2029 年全球癌症诊断液态切片市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第 25 章癌症诊断液态切片市场：结论与建议

  • 结论
  • 建议
    • 产品
    • 地方
    • 价格
    • 晋升
    • 人们

第26章 附录

简介目录
Product Code: o&s1496

Liquid biopsy for cancer diagnostics refers to a minimally invasive technique that enables the detection and monitoring of cancer through the analysis of biomarkers present in body fluids such as blood, urine, or saliva. This diagnostic approach is increasingly transforming cancer care by offering a less invasive alternative to traditional tissue biopsies, which often require surgical procedures.

The liquid biopsy for cancer diagnostics market consists of sales, by entities (organizations, sole traders and partnerships) of liquid biopsy for cancer diagnostics products and services that are utilized by healthcare professionals for early cancer detection, tracking disease progression, monitoring treatment efficacy and detecting recurrence. These diagnostic tools are especially advantageous for cases where tissue biopsy is challenging or impossible, such as in advanced-stage cancers or when monitoring for residual disease.

The global liquid biopsy for cancer diagnostics market was valued at $4,446.47 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 15.00%.

Government Initiatives For Research And Development In Healthcare

Government initiatives for research and development in healthcare supported the growth of the liquid biopsy for cancer diagnostics market during the historic period. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Government initiatives for research and development provide critical support for advancing liquid biopsy for cancer diagnostics by fostering innovation, collaboration, regulatory oversight, public awareness, access to healthcare services and data sharing. For instance, in November 2023, the UK and France announced a partnership to tackle significant challenges in cancer research. This collaboration between France's Institut National Du Cancer (INCa), a French national cancer institute and Cancer Research UK, a leading charity that funds research into all types of cancer in the UK, is dedicated to funding leading experts to address the most complex cancer cases. Together, they will contribute £8.6 million ($10.8 million) to support the global Cancer Grand Challenges initiative and advance world-class cancer research efforts. Therefore, government initiatives for research and development in healthcare supported the growth of the liquid biopsy for cancer diagnostics market.

High-Precision Liquid Biopsy For Identifying Cancer Biomarkers

Major companies operating in the liquid biopsy for cancer diagnostics market are focusing on developing high-precision liquid biopsy for identifying cancer biomarkers. High-precision liquid biopsy refers to advanced techniques used to analyze circulating biomarkers in bodily fluids, primarily blood, to detect and monitor cancer with a high degree of accuracy. For instance, in September 2024, Strand Life Sciences, an India-based genomics and bioinformatics software and services provider, launched the somatic advantage 74 Liquid Biopsy (SA74 LB) test. This high-precision liquid biopsy test detects circulating tumor deoxyribonucleic acid (ctDNA) in blood samples from cancer patients, analyzing 74 clinically significant genes to offer valuable insights for treatment decisions. The SA74 LB test is designed to be minimally invasive, requiring only a blood sample, thus providing a more convenient alternative to traditional tissue biopsies. Utilizing Unique Molecular Identifiers (UMIs) ensures high-accuracy detection of genetic variants, enabling clinicians to identify potential biomarkers and optimize treatment strategies effectively.

The global liquid biopsy for cancer diagnostics market is fairly fragmented, with a large number of small players in the market. The top ten competitors in the market made up 24.44% of the total market in 2023.

Liquid Biopsy For Cancer Diagnostics Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global liquid biopsy for cancer diagnostics market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for liquid biopsy for cancer diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The liquid biopsy for cancer diagnostics market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider liquid biopsy for cancer diagnostics market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by cancer, by sample and by end user.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the liquid biopsy for cancer diagnostics market.
  • Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis -Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by cancer, by end user and by sample in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for liquid biopsy for cancer diagnostics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Type: Product; Services
  • 2) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
  • 3)By Sample: Blood; Urine; Saliva
  • 4) By End User: Hospitals; Diagnostic Centers; Other End Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Guardant Health Inc.; Illumina Inc.; Exact Sciences Corporation
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; liquid biopsy for cancer diagnostics indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Liquid Biopsy For Cancer Diagnostics - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Liquid Biopsy For Cancer Diagnostics Market Definition And Segmentations
  • 6.4 Market Segmentation By Type
    • 6.4.1 Product
    • 6.4.2 Services
  • 6.5 Market Segmentation By Cancer
    • 6.5.1 Lung Cancer
    • 6.5.2 Breast Cancer
    • 6.5.3 Colon Cancer
    • 6.5.4 Other Cancers
  • 6.6 Market Segmentation By Sample
    • 6.6.1 Blood
    • 6.6.2 Urine
    • 6.6.3 Saliva
  • 6.7 Market Segmentation By End User
    • 6.7.1 Hospitals
    • 6.7.2 Diagnostic Centers
    • 6.7.3 Other End Users

7 Major Market Trends

  • 7.1 High-Precision Liquid Biopsy For Identifying Cancer Biomarkers
  • 7.2 Advancements In Automated Liquid Biopsy Technologies For Oncology And Prenatal Care
  • 7.3 Next-Generation Liquid Biopsy Tool Improves Cancer Screening Capabilities
  • 7.4 Technological Advancement In Liquid Biopsy For Personalized Cancer Treatment
  • 7.5 Enhancing Tumor Detection And Profiling With Liquid Biopsy

8 Liquid Biopsy For Cancer Diagnostics Market - Macro-Economic Scenario

  • 8.1 COVID-19 Impact On The Liquid Biopsy For Cancer Diagnostics Market
  • 8.2 Impact Of The War In Ukraine On The Liquid Biopsy For Cancer Diagnostics Market
  • 8.3 Impact Of High Inflation On The Liquid Biopsy For Cancer Diagnostics Market

9 Global Market Size and Growth

  • 9.1 Market Size
  • 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 9.2.1 Market Drivers 2019 - 2024
    • 9.2.2 Market Restraints 2019- 2024
  • 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 9.3.1 Market Drivers 2024 - 2029
    • 9.3.2 Market Restraints 2024 - 2029

10 Global Liquid Biopsy For Cancer Diagnostics Market Segmentation

  • 10.1 Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.3 Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.4 Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Liquid Biopsy For Cancer Diagnostics Market, Regional and Country Analysis

  • 11.1 Global Liquid Biopsy For Cancer Diagnostics Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.2 Global Liquid Biopsy For Cancer Diagnostics Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

  • 12.1 Summary
  • 12.2 Market Overview
    • 12.2.1 Region Information
    • 12.2.2 Market Information
    • 12.2.3 Background Information
    • 12.2.4 Government Initiatives
    • 12.2.5 Regulations
    • 12.2.6 Regulatory Bodies
    • 12.2.7 Major Associations
    • 12.2.8 Taxes Levied
    • 12.2.9 Corporate Tax Structure
    • 12.2.10 Investments
    • 12.2.11 Major Companies
  • 12.3 Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.6 Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market: Country Analysis
  • 12.7 China Market
  • 12.8 Summary
  • 12.9 Market Overview
    • 12.9.1 Country Information
    • 12.9.2 Market Information
    • 12.9.3 Background Information
    • 12.9.4 Government Initiatives
    • 12.9.5 Regulations
    • 12.9.6 Regulatory Bodies
    • 12.9.7 Major Associations
    • 12.9.8 Taxes Levied
    • 12.9.9 Corporate Tax Structure
    • 12.9.10 Investments
    • 12.9.11 Major Companies
  • 12.10 China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.12 China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 India Market
  • 12.14 India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.16 India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 Japan Market
  • 12.18 Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.20 Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Australia Market
  • 12.22 Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.24 Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Indonesia Market
  • 12.26 Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.27 Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.28 Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.29 South Korea Market
  • 12.30 South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.31 South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.32 South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

  • 13.1 Summary
  • 13.2 Market Overview
    • 13.2.1 Region Information
    • 13.2.2 Market Information
    • 13.2.3 Background Information
    • 13.2.4 Government Initiatives
    • 13.2.5 Regulations
    • 13.2.6 Regulatory Bodies
    • 13.2.7 Major Associations
    • 13.2.8 Taxes Levied
    • 13.2.9 Corporate tax structure
    • 13.2.10 Investments
    • 13.2.11 Major Companies
  • 13.3 Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.6 Western Europe Liquid Biopsy For Cancer Diagnostics Market: Country Analysis
  • 13.7 UK Market
  • 13.8 UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.10 UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.11 Germany Market
  • 13.12 Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.13 Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.14 Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.15 France Market
  • 13.16 France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.17 France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.18 France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.19 Italy Market
  • 13.20 Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.21 Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.22 Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.23 Spain Market
  • 13.24 Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.25 Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.26 Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

  • 14.1 Summary
  • 14.2 Market Overview
    • 14.2.1 Region Information
    • 14.2.2 Market Information
    • 14.2.3 Background Information
    • 14.2.4 Government Initiatives
    • 14.2.5 Regulations
    • 14.2.6 Regulatory Bodies
    • 14.2.7 Major Associations
    • 14.2.8 Taxes Levied
    • 14.2.9 Corporate Tax Structure
    • 14.2.10 Major companies
  • 14.3 Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.6 Eastern Europe Liquid Biopsy For Cancer Diagnostics Market: Country Analysis
  • 14.7 Russia Market
  • 14.8 Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.9 Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.10 Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

  • 15.1 Summary
  • 15.2 Market Overview
    • 15.2.1 Region Information
    • 15.2.2 Market Information
    • 15.2.3 Background Information
    • 15.2.4 Government Initiatives
    • 15.2.5 Regulations
    • 15.2.6 Regulatory Bodies
    • 15.2.7 Major Associations
    • 15.2.8 Taxes Levied
    • 15.2.9 Corporate Tax Structure
    • 15.2.10 Investments
    • 15.2.11 Major Companies
  • 15.3 North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.6 North America Liquid Biopsy For Cancer Diagnostics Market: Country Analysis
  • 15.7 USA Market
  • 15.8 Summary
  • 15.9 Market Overview
    • 15.9.1 Country Information
    • 15.9.2 Market Information
    • 15.9.3 Background Information
    • 15.9.4 Government Initiatives
    • 15.9.5 Regulations
    • 15.9.6 Regulatory Bodies
    • 15.9.7 Major Associations
    • 15.9.8 Taxes Levied
    • 15.9.9 Corporate Tax Structure
    • 15.9.10 Investments
    • 15.9.11 Major Companies
  • 15.10 USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.11 USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.12 USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.13 Canada Market
  • 15.14 Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.15 Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.16 Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate Tax Structure
    • 16.2.10 Major Companies
  • 16.3 South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.6 South America Liquid Biopsy For Cancer Diagnostics Market: Country Analysis
  • 16.7 Brazil Market
  • 16.8 Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.9 Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.10 Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Associations
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
    • 17.2.10 Major Companies
  • 17.3 Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.5 Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

  • 18.1 Summary
  • 18.2 Market Overview
    • 18.2.1 Region Information
    • 18.2.2 Market Information
    • 18.2.3 Background Information
    • 18.2.4 Government Initiatives
    • 18.2.5 Regulations
    • 18.2.6 Regulatory Bodies
    • 18.2.7 Major Associations
    • 18.2.8 Taxes Levied
    • 18.2.9 Corporate Tax Structure
    • 18.2.10 Major Companies
  • 18.3 Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.4 Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.5 Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape And Company Profiles

  • 19.1 Company Profiles
  • 19.2 F. Hoffman-La Roche Ltd
    • 19.2.1 Company Overview
    • 19.2.2 Products And Services
    • 19.2.3 Business Strategy
    • 19.2.4 Financial Overview
  • 19.3 Thermo Fisher Scientific Inc
    • 19.3.1 Company Overview
    • 19.3.2 Products And Services
    • 19.3.3 Business Strategy
    • 19.3.4 Financial Overview
  • 19.4 Guardant Health Inc
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
    • 19.4.3 Business Strategy
    • 19.4.4 Financial Overview
  • 19.5 Illumina Inc.
    • 19.5.1 Company Overview
    • 19.5.2 Products And Services
    • 19.5.3 Financial Overview
  • 19.6 Exact Sciences Corporation
    • 19.6.1 Company Overview
    • 19.6.2 Products And Services
    • 19.6.3 Business Strategy
    • 19.6.4 Financial Overview

20 Other Major And Innovative Companies

  • 20.1 Natera Inc.
    • 20.1.1 Company Overview
    • 20.1.2 Products And Services
  • 20.2 Johnson & Johnson Services Inc.
    • 20.2.1 Company Overview
    • 20.2.2 Products And Services
  • 20.3 Bio-Rad Laboratories Inc.
    • 20.3.1 Company Overview
    • 20.3.2 Products And Services
  • 20.4 Caris Life Science
    • 20.4.1 Company Overview
    • 20.4.2 Products And Services
  • 20.5 Sysmex Corporation
    • 20.5.1 Company Overview
    • 20.5.2 Products And Services
  • 20.6 Qiagen NV
    • 20.6.1 Company Overview
    • 20.6.2 Products And Services
  • 20.7 Myriad Genetic Laboratories Inc.
    • 20.7.1 Company Overview
    • 20.7.2 Products And Services
  • 20.8 Invitae Corporation
    • 20.8.1 Company Overview
    • 20.8.2 Products And Services
  • 20.9 Freenome Holdings Inc.
    • 20.9.1 Company Overview
    • 20.9.2 Products And Services
  • 20.1 Tempus Labs, Inc.
    • 20.10.1 Company Overview
    • 20.10.2 Products And Services
  • 20.11 MDxHealth SA
    • 20.11.1 Company Overview
    • 20.11.2 Products And Services
  • 20.12 NeoGenomics Laboratories Inc.
    • 20.12.1 Company Overview
    • 20.12.2 Products And Services
  • 20.13 ExosomeDx
    • 20.13.1 Company Overview
    • 20.13.2 Products And Services
  • 20.14 Biodesix Inc.
    • 20.14.1 Company Overview
    • 20.14.2 Products And Services
  • 20.15 Biocartis Group NV.
    • 20.15.1 Company Overview
    • 20.15.2 Products And Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

  • 23.1 Quest Diagnostics Acquired Haystack Oncology
  • 23.2 Exact Sciences Corporation Acquired Resolution Bioscience, Inc.
  • 23.3 Exact Sciences Corporation Acquired Thrive Earlier Detection

24 Opportunities And Strategies

  • 24.1 Global Liquid Biopsy For Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 24.2 Global Liquid Biopsy For Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 24.3 Global Liquid Biopsy For Cancer Diagnostics Market In 2029 - Growth Strategies
    • 24.3.1 Market Trend Based Strategies
    • 24.3.2 Competitor Strategies

25 Liquid Biopsy For Cancer Diagnostics Market, Conclusions And Recommendations

  • 25.1 Conclusions
  • 25.2 Recommendations
    • 25.2.1 Product
    • 25.2.2 Place
    • 25.2.3 Price
    • 25.2.4 Promotion
    • 25.2.5 People

26 Appendix

  • 26.1 Geographies Covered
  • 26.2 Market Data Sources
  • 26.3 Research Methodology
  • 26.4 Currencies
  • 26.5 The Business Research Company
  • 26.6 Copyright and Disclaimer